Deutsche Bank raised its price target on Biohaven Ltd. on July 6, 2026, while Biohaven trails Xenon's competing program by two years.
1 report, 1 independent
Updated Jul 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Deutsche Bank raised its price target on Biohaven Ltd. on July 6, 2026, while Biohaven trails Xenon's competing program by two years.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Deutsche Bank
German global banking and financial services company
-
Xenon
nightclub in New York City
Nothing else this week.
Related events
- Deutsche Bank downgraded stock and Needham cut price targets citing safety concerns regarding Xenon's product ahead of its NDA meeting.
- Stifel reiterated a Buy rating and target price for Spyre Therapeutics, while Deutsche Bank lowered targets following company results.
- Deutsche Bank lifted its price target on ABM on September 22, 2026.
- Deutsche Bank restated a buy rating on Performance Food Group Company on August 25, 2026.